Issue Date: March 17, 2008
British Drug Firm Acquires Cytogen
EUSA Pharma, based in Oxford, England, has agreed to buy Cytogen for $22.6 million. Princeton, N.J.-based Cytogen has three oncology and pain control products on the market in the U.S. "The acquisition of Cytogen is of great strategic importance for EUSA as it completes the building of our transatlantic commercialization infrastructure," EUSA CEO Bryan Morton says. To help pay for the deal, EUSA raised more than $50 million in an investment round led by TVM Capital.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society